Deletion of the q23-24 region of human chromosome 10 is one of the most frequent genetic alterations in prostate cancer, suggesting that inactivation of a tumor suppressor gene in this region is involved in the development or progression of this carcinoma. A candidate gene, PTEN/ MMAC1, has been identi®ed from this chromosomal region; mutations of this gene have been found in various advanced tumors and cell lines including those of prostate cancer. To further de®ne the role of PTEN/ MMAC1 in the development of prostate cancer and its spectrum of genetic alterations, we analysed 40 pT2 or pT3 prostate tumors for allelic loss, mutations, and homozygous deletions using PCR-based methods. Six tumors showed loss of heterozygosity for one of the ten markers analysed, while one tumor showed loss of two markers. None of the markers within PTEN/MMAC1 was lost. Direct sequencing of PCR ampli®ed exons and intron/exon junctions of all 40 tumors revealed three sequence variants, one of which was a point mutation in exon 9, while the other two were polymorphisms. Using multiplex PCR, no homozygous deletions were detected in any of the neoplasms. Our results showing a low frequency of alterations of PTEN/MMAC1 in pT2 and pT3 prostate cancers suggest that this gene plays an insigni®cant role in the development of most low stage carcinomas of the prostate.
Introduction
Prostate cancer is the most commonly diagnosed nonskin carcinoma, and is the second leading cause of cancer death in American men (Parker et al., 1997) . Genetic analysis has identi®ed several chromosomal regions such as 8p12 ± 21, 10q22 ± 24, 16q22 ± 24, and 7q31 whose deletions appear to be involved in prostatic carcinogenesis (Dong et al., 1997b) . One of the most frequently deleted loci resides in the q22 ± 24 region of chromosome 10, which was ®rst identi®ed in prostate tumors by conventional cytogenetic analysis (Atkin and Baker, 1985; Lundgren et al., 1988) . Deletion of this region has been repeatedly demonstrated by cytogenetic examination; for example, deletions were detected in 8 of 89 short-term cultures of prostate carcinomas (Arps et al., 1993; Lundgren et al., 1992) . Loss of heterozygosity (LOH) analysis has also shown deletions in the 10q23 ± 25 region, occurring in 20 ± 62% of prostate tumors, especially those that are of advanced stage (Bergerheim et al., 1991; Cunningham et al., 1996; Gray et al., 1995; Lacombe et al.,1996; Trybus et al., 1996) . In one of these studies, the deletion was de®ned at the 10q23 ± 24 boundary (Gray et al., 1995) . Introduction of human chromosome 10 into tumor cells of prostate resulted in the suppression of tumor growth or metastasis; 10q23 was within the region responsible for tumor or metastasis suppression (Murakami et al., 1996; Nihei et al., 1995) . These results suggest that loss of gene function in the q23 ± 24 region of chromosome 10 plays a role in the development or progression of prostate cancer.
A candidate tumor suppressor gene, PTEN/ MMAC1, was recently identi®ed from the q23 region of chromosome 10, and its mutation was noted in various advanced tumors and cell lines including several prostate cancer cell lines Steck et al., 1997) . Mutations of PTEN/MMAC1 have been detected in some carcinomas of the breast, prostate, and endometrium, and in melanoma and glioblastoma Guldberg et al., 1997; Liu et al., 1997; Rasheed et al., 1997; Rhei et al., 1997; Risinger et al., 1997; Suzuki et al.,1998; Tashiro et al.,1997; Teng et al., 1997; Wang et al., 1997) . In addition, mutation of PTEN/MMAC1 may be responsible for the development of Cowden disease Nelen et al., 1997; Tsou et al., 1997) and Bannayan-Zonana syndrome (Arch et al., 1997; Marsh et al., 1997) . In a recent analysis of 60 localized prostate cancers and 20 lymph node metastases, Cairns et al. reported that 3 of 11 (27%) localized tumors with LOH and 7 of 12 (58%) metastatic cancers with LOH had mutations or homozygous deletions of PTEN/MMAC1 . To further de®ne the role of PTEN/ MMAC1 in the development of prostate cancer and the spectrum of its mutations, we analysed 40 pT2 or pT3 prostate tumors for LOH, mutations, and homozygous deletions. Our results indicate that LOH and somatic mutations of PTEN/MMAC1 are infrequent in this group of low-stage tumors, and that alteration of PTEN/MMAC1 is not an early event in prostatic carcinogenesis.
Results and Discussion
We analysed allelic loss of PTEN/MMAC1 by PCR using microsatellite markers within or closely¯anking the gene. The two markers within PTEN/MMAC1 showed no LOH in any of the 40 cancers. One of them (D10S2491) showed 60% (24 of 40) polymorphism, while the other (D10S2492) showed only 2.5% (1 out of 40 cases) polymorphism. Most of the tumors (33 of 40) showed no LOH for any of the 10 polymorphic markers analysed. Six cases had LOH for one of the markers, while one tumor showed LOH with two markers. For this latter cancer, both lost markers were centromeric to PTEN/MMAC1, which excludes the possibility of identifying homozygous deletion by LOH analysis (Cairns et al., 1995 . The D10S581 marker was the most frequently deleted, having 15% LOH (4 of 26 informative cases). However, this marker was more centromeric and was farthest away from PTEN/MMAC1. The frequency of LOH (18%) in our study is similar to that reported in another series of clinically localized prostate cancers .
We then analysed the sequence of PTEN/MMAC1 exons and intron/exon junctions to search for point mutations or small deletions in all the 40 tumors, as some mutations (especially small deletions) may occur without LOH, and frequent PTEN/MMAC1 mutations have been found in cell lines and metastases of prostate cancer Steck et al., 1997) . Each PTEN/MMAC1 exon and small stretches of¯anking introns were ampli®ed by nested PCR from all 40 tumor samples and were sequenced. The second exon of the PTEN/MMAC1 was also ampli®ed and sequenced for the LNCaP prostate cancer cell line, and the c.132C4T base change was also detected using our procedures (data not shown). Direct sequencing of the PCR products from the 40 tumors revealed only three variants of PTEN/MMAC1 ( Figure  1 ). One was a germline polymorphism (seen in both normal and tumor cells), which resulted in a cytosine instead of thymine at position 1104 (exon 9, codon 368) but no change in the type of amino acid. The other two variants were somatic changes, i.e., they were seen only in tumor cells but not in matched normal cells. One of these was a point mutation of c.1106T4G in exon 9, resulting a change of valine to glycine at codon 369 (V369G). This cancer was negative for capsule penetration, had negative surgical margins, and lacked seminal vesicle invasion and lymph node metastasis; it was high grade (Gleason score 8), however. The other variant was c.480C4T (codon 160) in exon 5, which did not result in a change in the polypeptide sequence of PTEN/MMACI. Neither of the somatic changes was from a tumor with allelic loss of PTEN/MMAC1.
It is not known what eect the c.1106T4G mutation might have on the function of the PTEN/ MMAC1 protein. However, the ®nding of only one of 40 cancers with a mutation in PTEN/MMAC1 suggests that somatic mutation of this gene is an infrequent event in resected prostate cancers. Each of the tumors in this study was from a patient who did not receive any therapy prior to surgery, and most were low stage, as 97.5% lacked lymph node metastasis, 83% had not spread to seminal vesicles, and 64% did not have capsule penetration. Eighty-two percent of the cancers had a Gleason score of 5 ± 7. Our ®ndings are consistent with those in a previous report in which most of the mutations of PTEN/MMAC1 were found in metastases of prostate cancer and mutations were rare in localized tumors .
It was possible that homozygous deletions were present in some of our tumors but were not detected by the analysis of DNA sequences. To exclude this possibility, we developed a multiplex PCR approach to amplify exons 1 and 7 of PTEN/MMAC1 and exon 7 of KAI1, which is located on human chromosome 11 and was found not to be deleted even in metastases of prostate cancer (Dong et al., 1997a) . We used DNA from the A172 glioblastoma cell line, which has a homozygous deletion of exons 3 ± 9 but not exon 1 and 2 of PTEN/MMAC1 , as a control for the eciency of this method. As seen in Figure 2 , when A172 DNA constituted 70% (lanes 2 and 8) or 50% (lanes 3 and 9) of DNA populations in a sample, PCR bands of exon 7 (middle band in each lane) show similar (lanes 2 and 8) or a little greater (lanes 3 and 9) intensities compared to PCR bands of KAI1 control (bottom band). Exon 7 bands in DNA with 25 % (lanes 4 and 10) or no (lanes 5 and 11) deleted PTEN/ MMAC1 show signi®cantly greater intensities compared to KAI1 bands. Meanwhile, the band of exon 1 (upper band) shows similar intensity to that of KAI1 control when PTEN/MMAC1 is intact. These results indicate that this method could detect a homozygous Figure 2 Analysis of PTEN/MMAC1 for homozygous deletion by multiplex PCR. Lanes 1 and 7 show PCR products from DNA of the A172 glioblastoma cell line, which has a homozygous deletion of exons 3 ± 9 of PTEN/MMAC1. Lanes 5 and 11 were from DNA of a human placenta, which had intact PTEN/ MMAC1. Lanes 2 and 8, 3 and 9, and 4 and 10 had various ratios of A172 DNA and placenta DNA (3 : 1, 1 : 1, and 1 : 3 respectively). Lanes 1 ± 5 had 50 ng of genomic DNA for PCR, while lanes 7 ± 11 had 10 ng. Lanes 12 ± 15 were PCR products of 4 tumor samples, which show no homozygous deletion of PTEN/ MMAC1. Lane 6 was 1 kb DNA ladder (Life Technologies). Sizes of PCR products are indicated in basepairs (bp) to the left of the pictures deletion when DNA with the particular deletion constituted 50% or more of the total DNA in a sample. Using this method, we found no homozygous deletions in any of the 40 tumors (Figure 2 ), which typically contained more than 70% of tumor cells.
The low frequency of mutations of PTEN/MMAC1 in pT2 and pT3 prostate cancers suggests that its alteration plays an insigni®cant role in the development of most low-stage prostate cancers. Inactivation of this gene by promoter methylation has also been shown to be absent in localized prostate cancers . A higher rate of mutation of PTEN/MMAC1 has been reported in some prostate cancer metastases Suzuki et al., 1998) , suggesting that PTEN/MMAC1 is involved in the progression of prostate tumors. Whether the infrequent mutation of PTEN/MMAC1 in resected, low-stage prostate cancers is predictive of tumor recurrence is unknown. In addition, exactly what functional advantage, if any, alteration of PTEN/MMAC1 imparts to some advanced cancers needs additional study.
Materials and methods

Tumor samples
Forty pairs of matched zinc formalin-®xed, paranembedded normal and cancerous prostate tissues from radical prostatectomy specimens from previously untreated patients were used in this study. Patient age ranged from 42 ± 74 years (median 60). The pathologic characteristics of the tumors were as follows: Gleason score: 82% had scores of 5 ± 7 while 18% had score 8 or 9; lymph node metastasis: 1 of 40 cases; seminal vesicle invasion: 83% negative and 17% positive; and capsule penetration: 64% negative and 36% positive. The tumors were pathologically staged according to the most recent AJCC recommendations (American Joint Committee on Cancer, 1997). Tumor cells were collected from 7 mm H and E stained sections using a previously described protocol for preparation of histological sections on glass slides prior to dissection (Moskaluk and Kern, 1997) . Using a microscopic dissection method, tumor samples were selected to ensure a minimum number of 70% neoplastic cells. Normal cells from lymph nodes or seminal vesicles in almost 90% of the cases, and from normal prostate in the remainder were obtained from paran blocks that contained no neoplastic cells.
LOH analysis
Genomic DNA was isolated from specimens by adding proteinase K buer, incubating at 378C for 2 ± 3 days, extracting by phenol and chloroform, and precipitating with ethanol. Ten polymorphic microsatellite markers Steck et al., 1997) were used for LOH analysis, four of which (D10S581, D10S537, D10S1744, and D10S215) were centromeric to the PTEN/MMAC1 gene, two (D10S2491 and D10S2492) were within the gene, and four (D10S541, D10S583, D10S185, and D10S221) were telomeric to the gene. Each PCR analysis contained 10 ± 50 ng of genomic DNA; 16PCR buer (1.5 mM MgCl 2 ); 0.4 mM of each primer; 200 mM of dCTP, dGTP, and dTTP; 5mM of dATP; 2.5 mCi of a-35 S-dATP (1000 mCi/mmol); and 1 unit of Taq DNA polymerase in a volume of 10 ml. Thirty to 40 cycles, each consisting of denaturation at 948C for 30 s, annealing at 508C or 558C for 30 s, and extension at 728C for 1 min, were performed. PCR products were separated in a 6% denaturing polyacrylamide gel and autoradiographed. LOH was determined when the signal for one allele in the tumor was signi®cantly reduced or absent when compared to that for the nonneoplastic cells.
Mutational analysis
Five ng of genomic DNA from each tumor sample was ampli®ed by PCR in a volume of 25 mg using outer primer pairs for each exon of PTEN/MMACl. The resulting PCR products were diluted twofold; 1 ml of the dilution was ampli®ed in a volume of 100 ml using nested primers of each exon. Both outer and nested primers were as previously described except that the sequences of M13 forward and reverse primers were omitted for all the nested primers . After initial denaturation at 958C for 5 min, 35 cycles of denaturation at 948C for 30 s, annealing at 558C for 30 s, and extension at 728C for 1 min was performed for both PCR ampli®cations. DNA from the second round of PCR was puri®ed using the Wizard PCR Preps DNA Puri®cation System (Promega, Madison, WI), denatured with a solution of 2 M NaOH and 2 mM EDTA, precipitated with 5 M ammonium acetate and ethanol, and resuspended in 24 ml of H 2 O. Four ml of denatured DNA was mixed with 1 ml of 1 mM either 5' or 3' nested primer, and was then subjected to DNA sequence analysis using TaqTrack Sequencing Systems (Promega). Sequencing data were analysed using the ScanDNASIS and MacDNASIS softwares (Hitachi Software, San Bruno, CA). When a change was identi®ed on a sequencing ®lm for a tumor sample, PCR and sequencing of genomic DNA for the sample were repeated to verify the change. Matched normal DNA was also ampli®ed and sequenced along with the repeated tumor sample.
Homozygous deletion analysis
Ten to ®fty nanograms of genomic DNA was ampli®ed by PCR in a volume of 25 ml with 16PCR buer; 1.5 mM MgCl 2 ; 200 mM each dNTP; 0.4 mM each of primers for exon 1 and 7 of PTEN/MMAC1; 0.2 mM each of primers for exon 7 of KAI1 (33), and 1.5 units of Taq DNA polymerase. Sequences of primers were as follows: PTEN/ MMAC1 exon 1, 5'-CAGCCGTTCGGAGGATTAA-3' and 5'-ATATGACCTAGCAACCTGACCA-3'; exon 7, 5'-ATCGTTTTTGACAGTTTG-3' and 5'-TAATGTCTCAC-CAATGCCA-3'; and KAI1 exon 7: 5'-TGGGCACG-GGTTTCAGGAAAT-3' and 5'-TGCAGAGAGCCCCA-AATGCA-3'. A hot start approach was applied, i.e., tubes with all reaction components except Taq enzyme were heated at 958C for 7 min and then kept at 808C in the GeneAmp PCR System 2400 (Perkin Elmer, Foster City, CA). Taq enzyme (at 3 U/ml) was added to each tube during the 808C holding period. After enzyme was added, 30 cycles at 948C for 30 s, 558C for 30 s, and 728C for 1 min were performed. Twenty ml of PCR products were separated in a 1.5% agarose gel, which was then documented using the AlphaImager's Digital Imaging and Analysis Systems (Alpha Innotech, San Leandro, CA).
